分子靶点 T-cell-specific surface glycoprotein CD28 酶 A disintegrin and metalloproteinase with thrombospondin motifs 4 药物类型 Small Molecule 研发阶段 Approved 药物描述 Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine ...
Doses of tinzaparin in excess of the manufacturer's recommended weight-based dose were required to maintain therapeutic levels of anticoagulation.P.S. GibsonK. NewellD.X. SamA. MansoorX. JiangS. TangS. RoThrombosis ResearchGibson PS, Newell K, Sam DX, Mansoor A, Jiang X, Tang S, et ...
Do not double the dose to catch up. Storage Store at room temperature. Keep all medications away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. ...
INTERVENTIONS Tinzaparin (175 IU/kg) once daily for 6 months vs conventional therapy with tinzaparin (175 IU/kg) once daily for 5 to 10 days followed by warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic range (2.0-3.0) for 6 months. MAIN ...
Low-molecular-weight (LMWH) has been suggested as providing safe, efficient, convenient, and possibly more cost-effective anticoagulation for hemodialysis (HD) than unfractionated (UFH) with a single bolus dose at the start of hemodialysis effectively prevents clot in the dialyzer and bubble trap wi...
Tinzaparin sodium (Innohep®) is a low molecular weight heparin (LMWH) that is effective in the prevention and treatment of deep vein thrombosis (DVT)
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic... Low-molecular-weight heparins (LMWHs) accumulate in patients with impaired renal function. As this accumulation depends on heparin chain length ...
dose group (p= 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose ...
Thromboprophylaxis with low molecular weight heparin (LMWH) is the standard of care, but due to the vast heterogeneity of lung cancer patients, there is no consensus on the optimal dose and duration of the treatment. Abstract Background: The aim of this study was to record and assess the ...
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer.IMPORTANCE Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large ...